Benjamin F. Edwards & Company Inc. Buys 1,987 Shares of Boston Scientific Co. (NYSE:BSX)

Benjamin F. Edwards & Company Inc. grew its position in Boston Scientific Co. (NYSE:BSX) by 17.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,340 shares of the medical equipment provider’s stock after purchasing an additional 1,987 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Boston Scientific were worth $771,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. BSW Wealth Partners increased its position in Boston Scientific by 2.3% during the fourth quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock worth $428,000 after acquiring an additional 165 shares during the period. Valley National Advisers Inc. lifted its position in shares of Boston Scientific by 2.3% in the 4th quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock worth $435,000 after acquiring an additional 170 shares during the period. Aveo Capital Partners LLC grew its holdings in shares of Boston Scientific by 1.3% during the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock worth $742,000 after purchasing an additional 171 shares in the last quarter. Whitaker Myers Wealth Managers LTD. increased its position in shares of Boston Scientific by 4.6% during the fourth quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock valued at $237,000 after purchasing an additional 179 shares during the period. Finally, Brighton Jones LLC raised its stake in shares of Boston Scientific by 5.4% in the third quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock valued at $211,000 after purchasing an additional 205 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold 78,384 shares of company stock worth $5,395,560 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BSX shares. Oppenheimer boosted their price target on shares of Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a report on Thursday, February 1st. Argus raised their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada upped their price objective on Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Finally, Raymond James upped their price target on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $75.09.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $73.43 on Wednesday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $74.39. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $107.73 billion, a PE ratio of 61.71, a PEG ratio of 2.51 and a beta of 0.77. The stock’s fifty day simple moving average is $68.68 and its 200 day simple moving average is $61.74.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.